0	7	Effects	Effect	NNPS
8	10	of	of	IN
11	25	interleukin-10	interleukin-10	NN
26	28	on	on	IN
29	34	human	human	JJ
35	45	peripheral	peripheral	JJ
46	51	blood	blood	NN
52	63	mononuclear	mononuclear	JJ
64	68	cell	cell	NN
69	78	responses	response	NNS
79	81	to	to	TO
82	94	Cryptococcus	Cryptococcus	NNP
95	105	neoformans	neoforman	NNS
105	106	,	,	,
107	114	Candida	Candida	NNP
115	123	albicans	albicans	NNP
123	124	,	,	,
125	128	and	and	CC
129	147	lipopolysaccharide	lipopolysaccharide	NN
147	148	.	.	.

150	162	Deactivation	Deactivation	NNP
163	165	of	of	IN
166	177	mononuclear	mononuclear	JJ
178	188	phagocytes	phagocyte	NNS
189	191	is	be	VBZ
192	200	critical	critical	JJ
201	203	to	to	TO
204	209	limit	limit	VB
210	213	the	the	DT
214	226	inflammatory	inflammatory	JJ
227	235	response	response	NN
236	239	but	but	CC
240	243	can	can	MD
244	246	be	be	VB
247	258	detrimental	detrimental	JJ
259	261	in	in	IN
262	265	the	the	DT
266	270	face	face	NN
271	273	of	of	IN
274	285	progressive	progressive	JJ
286	295	infection	infection	NN
295	296	.	.	.

297	299	We	we	PRP
300	308	compared	compare	VBD
309	312	the	the	DT
313	320	effects	effect	NNS
321	323	of	of	IN
324	327	the	the	DT
328	340	deactivating	deactivate	VBG
341	349	cytokine	cytokine	NN
350	361	interleukin	interleukin	NN
362	364	10	10	CD
365	366	(	(	(
366	371	IL-10	il-10	NN
371	372	)	)	)
373	375	on	on	IN
376	381	human	human	JJ
382	392	peripheral	peripheral	JJ
393	398	blood	blood	NN
399	410	mononuclear	mononuclear	JJ
411	415	cell	cell	NN
416	417	(	(	(
417	421	PBMC	PBMC	NNP
421	422	)	)	)
423	432	responses	response	NNS
433	435	to	to	TO
436	454	lipopolysaccharide	lipopolysaccharide	NN
455	456	(	(	(
456	459	LPS	LPS	NNP
459	460	)	)	)
460	461	,	,	,
462	474	Cryptococcus	Cryptococcus	NNP
475	485	neoformans	neoforman	NNS
485	486	,	,	,
487	490	and	and	CC
491	498	Candida	Candida	NNP
499	507	albicans	albicans	NNP
507	508	.	.	.

509	514	IL-10	IL-10	NNP
515	523	effected	effect	VBD
524	538	dose-dependent	dose-dependent	JJ
539	549	inhibition	inhibition	NN
550	552	of	of	IN
553	558	tumor	tumor	NN
559	567	necrosis	necrosis	NN
568	574	factor	factor	NN
575	580	alpha	alpha	NN
581	582	(	(	(
582	591	TNF-alpha	TNF-alpha	NNP
591	592	)	)	)
593	600	release	release	NN
601	603	in	in	IN
604	608	PBMC	PBMC	NNP
609	619	stimulated	stimulate	VBN
620	622	by	by	IN
623	626	LPS	LPS	NNP
627	630	and	and	CC
631	633	C.	c.	FW
634	644	neoformans	neoformans	FW
644	645	,	,	,
646	650	with	with	IN
651	662	significant	significant	JJ
663	673	inhibition	inhibition	NN
674	678	seen	see	VBN
679	683	with	with	IN
684	687	0.1	0.1	CD
688	692	U/ml	U/ml	NNP
693	696	and	and	CC
697	704	greater	great	JJR
705	709	than	than	IN
710	712	90	90	CD
712	713	%	%	NN
714	724	inhibition	inhibition	NN
725	730	noted	note	VBD
731	735	with	with	IN
736	738	10	10	CD
739	743	U/ml	U/ml	NNP
743	744	.	.	.

745	747	In	in	IN
748	756	contrast	contrast	NN
756	757	,	,	,
758	762	even	even	RB
763	765	at	at	IN
766	771	doses	dose	NNS
772	774	as	as	RB
775	779	high	high	JJ
780	782	as	as	IN
783	786	100	100	CD
787	791	U/ml	U/ml	NNP
791	792	,	,	,
793	798	IL-10	IL-10	NNP
799	808	inhibited	inhibit	VBD
809	818	TNF-alpha	TNF-alpha	NNP
819	826	release	release	NN
827	829	in	in	IN
830	838	response	response	NN
839	841	to	to	TO
842	844	C.	c.	FW
845	853	albicans	albicans	FW
854	856	by	by	IN
857	861	only	only	RB
862	864	50	50	CD
864	865	%	%	NN
865	866	.	.	.

867	872	IL-10	IL-10	NNP
873	883	profoundly	profoundly	RB
884	893	inhibited	inhibit	VBD
894	901	release	release	NN
902	904	of	of	IN
905	913	IL-1beta	IL-1beta	NNP
914	918	from	from	IN
919	923	PBMC	PBMC	NNP
924	934	stimulated	stimulate	VBN
935	937	by	by	IN
938	941	all	all	DT
942	947	three	three	CD
948	955	stimuli	stimulus	NNS
955	956	.	.	.

957	966	TNF-alpha	TNF-alpha	NNP
967	971	mRNA	mRNA	NNP
972	975	and	and	CC
976	983	release	release	NN
984	987	was	be	VBD
988	997	inhibited	inhibit	VBN
998	1002	even	even	RB
1003	1005	if	if	IN
1006	1011	IL-10	IL-10	NNP
1012	1015	was	be	VBD
1016	1021	added	add	VBN
1022	1024	up	up	RB
1025	1027	to	to	TO
1028	1029	8	8	CD
1030	1031	h	h	NN
1032	1037	after	after	IN
1038	1050	cryptococcal	cryptococcal	JJ
1051	1062	stimulation	stimulation	NN
1062	1063	.	.	.

1064	1066	In	in	IN
1067	1075	contrast	contrast	NN
1075	1076	,	,	,
1077	1087	inhibition	inhibition	NN
1088	1090	of	of	IN
1091	1095	IL-1	il-1	NN
1096	1100	beta	beta	NN
1101	1105	mRNA	mRNA	NNP
1106	1109	was	be	VBD
1110	1112	of	of	IN
1113	1119	lesser	less	JJR
1120	1129	magnitude	magnitude	NN
1130	1133	and	and	CC
1134	1142	occurred	occur	VBD
1143	1147	only	only	RB
1148	1152	when	when	WRB
1153	1158	IL-10	IL-10	NNP
1159	1162	was	be	VBD
1163	1168	added	add	VBN
1169	1175	within	within	IN
1176	1177	2	2	CD
1178	1179	h	h	NN
1180	1182	of	of	IN
1183	1195	cryptococcal	cryptococcal	JJ
1196	1207	stimulation	stimulation	NN
1207	1208	.	.	.

1209	1214	IL-10	IL-10	NNP
1215	1224	inhibited	inhibit	VBD
1225	1238	translocation	translocation	NN
1239	1241	of	of	IN
1242	1251	NF-kappaB	NF-kappaB	NNP
1252	1254	in	in	IN
1255	1263	response	response	NN
1264	1266	to	to	TO
1267	1270	LPS	LPS	NNP
1271	1274	but	but	CC
1275	1278	not	not	RB
1279	1282	the	the	DT
1283	1289	fungal	fungal	JJ
1290	1297	stimuli	stimulus	NNS
1297	1298	.	.	.

1299	1302	All	all	DT
1303	1308	three	three	CD
1309	1316	stimuli	stimulus	NNS
1317	1324	induced	induce	VBD
1325	1330	IL-10	il-10	NN
1331	1341	production	production	NN
1342	1344	in	in	IN
1345	1349	PBMC	PBMC	NNP
1349	1350	,	,	,
1351	1359	although	although	IN
1360	1364	over	over	IN
1365	1372	10-fold	10-fold	RB
1373	1377	less	less	JJR
1378	1383	IL-10	il-10	NN
1384	1387	was	be	VBD
1388	1396	released	release	VBN
1397	1399	in	in	IN
1400	1408	response	response	NN
1409	1411	to	to	TO
1412	1414	C.	c.	FW
1415	1425	neoformans	neoformans	FW
1426	1434	compared	compare	VBN
1435	1439	with	with	IN
1440	1443	LPS	LPS	NNP
1444	1447	and	and	CC
1448	1450	C.	C.	NNP
1451	1459	albicans	albicans	NNP
1459	1460	.	.	.

1461	1465	Thus	thus	RB
1465	1466	,	,	,
1467	1472	while	while	IN
1473	1478	IL-10	IL-10	NNP
1479	1482	has	have	VBZ
1483	1495	deactivating	deactivate	VBG
1496	1503	effects	effect	NNS
1504	1506	on	on	IN
1507	1511	PBMC	PBMC	NNP
1512	1521	responses	response	NNS
1522	1524	to	to	TO
1525	1528	all	all	DT
1529	1534	three	three	CD
1535	1542	stimuli	stimulus	NNS
1542	1543	,	,	,
1544	1553	disparate	disparate	JJ
1554	1563	stimulus-	stimulus-	NN
1564	1567	and	and	CC
1568	1585	response-specific	response-specific	JJ
1586	1594	patterns	pattern	NNS
1595	1597	of	of	IN
1598	1610	deactivation	deactivation	NN
1611	1614	are	be	VBP
1615	1619	seen	see	VBN
1619	1620	.	.	.

1621	1631	Inhibition	Inhibition	NNP
1632	1634	by	by	IN
1635	1640	IL-10	IL-10	NNP
1641	1643	of	of	IN
1644	1659	proinflammatory	proinflammatory	JJ
1660	1668	cytokine	cytokine	NN
1669	1676	release	release	NN
1677	1684	appears	appear	VBZ
1685	1687	to	to	TO
1688	1693	occur	occur	VB
1694	1696	at	at	IN
1697	1700	the	the	DT
1701	1706	level	level	NN
1707	1709	of	of	IN
1710	1714	gene	gene	NN
1715	1728	transcription	transcription	NN
1729	1732	for	for	IN
1733	1742	TNF-alpha	TNF-alpha	NNP
1743	1746	and	and	CC
1747	1751	both	both	DT
1752	1769	transcriptionally	transcriptionally	RB
1770	1773	and	and	CC
1774	1795	posttranscriptionally	posttranscriptionally	RB
1796	1799	for	for	IN
1800	1808	IL-1beta	IL-1beta	NNP
1808	1809	.	.	.